Point72 Asset Management L.P. purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 4,883,197 shares of the company's stock, valued at approximately $17,677,000. Point72 Asset Management L.P. owned 5.82% of Atyr PHARMA at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. bought a new position in shares of Atyr PHARMA during the fourth quarter worth about $53,093,000. Tikvah Management LLC acquired a new position in Atyr PHARMA during the 4th quarter worth approximately $8,908,000. Alyeska Investment Group L.P. bought a new position in shares of Atyr PHARMA during the 4th quarter worth approximately $4,628,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at approximately $3,620,000. Finally, Octagon Capital Advisors LP bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $3,258,000. 61.72% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on ATYR shares. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Monday. Finally, Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $18.60.
Check Out Our Latest Stock Report on Atyr PHARMA
Atyr PHARMA Stock Performance
NASDAQ ATYR traded down $0.07 during trading on Friday, reaching $3.74. 400,717 shares of the company's stock were exchanged, compared to its average volume of 928,966. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The business has a 50 day moving average price of $3.25 and a 200-day moving average price of $3.41. The stock has a market capitalization of $332.43 million, a P/E ratio of -3.97 and a beta of 0.79. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $4.66.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. Sell-side analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.
About Atyr PHARMA
(
Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
